Heron Therapeutics announced preliminary, unaudited fourth quarter and full-year 2025 net revenue.
The growth in Q4 2025 was driven by momentum in the Acute Care franchise with ZYNRELEF® and APONVIE®.
Net revenue for the three months ended December 31, 2025, was approximately $40.5 million with ZYNRELEF® contributing $12.5 million.
Full-year 2025 net revenue reached approximately $154.9 million with significant growth from ZYNRELEF®.
Significant Revenue Growth
Net revenue for Q4 2025 was $40.5 million, reflecting growth driven by ZYNRELEF® and APONVIE®.
ZYNRELEF® Performance
ZYNRELEF® showed a substantial revenue increase in Q4, up by around 35% compared to Q3 2025.
Product Portfolio Success
Heron's product portfolio, including ZYNRELEF®, APONVIE®, CINVANTI®, and SUSTOL®, contributed to the revenue achievements in Q4 2025.
FDA Approvals and Expansions
ZYNRELEF® received approvals for expanded indications in December 2021 and January 2024, enhancing its market potential.
Business Progress
Heron emphasized progress across all areas of its business in 2025, reflecting positive trends and growth opportunities.
- ZYNRELEF® emerged as a key revenue driver for Heron in Q4 2025, showcasing its market acceptance and potential.
- The company's focus on Acute Care products like ZYNRELEF® and APONVIE® was instrumental in driving overall revenue growth.
- With successful FDA approvals and expanding indications, Heron's product portfolio demonstrates resilience and innovation in addressing healthcare needs.
Heron Therapeutics achieved notable revenue growth in Q4 2025, primarily attributed to the performance of ZYNRELEF® and other key products. The company's strong focus on innovation and market expansion indicates promising trends for future growth.